Multichannel imaging to quantify four classes of pharmacokinetic distribution in tumors

Journal of Pharmaceutical Sciences

Volumn 103, Issue 10, 2014, Pages 3276-3286

  Bhatnagar, Sumit ^a   Deschenes, Emily ^a   Liao, Jianshan ^a   Cilliers, Cornelius ^a   Thurber, Greg M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Drug transport; Fluorescence microscopy; Imaging methods; In vivo in vitro correlations (IVIVC); Krogh cylinder; Mathematical model; Predictive partial differential equation simulations

Indexed keywords

FLUORESCENCE MICROSCOPY; HUMAN; METABOLISM; NEOPLASM; PHARMACOKINETICS;

HUMANS; MICROSCOPY, FLUORESCENCE; NEOPLASMS; PHARMACOKINETICS;

EID: 84930171216     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24086     Document Type: Article

References (91)

1. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. 2011. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91(3):1071-1121.
2. Secomb TW, Hsu R, Park EYH, Dewhirst MW. 2004. Green's function methods for analysis of oxygen delivery to tissue by microvascular networks. Ann Biomed Eng 32(11):1519-1529.
3. Helmlinger G, Sckell A, Dellian M, Forbes N, Jain RK. 2002. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 8:1284-1291.
4. Jain RK. 1999. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1:241-263.
5. Minchinton AI, Tannock IF. 2006. Drug penetration in solid tumours. Nat Rev Cancer 6(8):583-592.
6. Ohtani H. 1998. Stromal reaction in cancer tissue: Pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions. Pathol Int 48(1):1-9.
7. Grantab R, Sivananthan S, Tannock IF. 2006. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res 66(2):1033-1039.
8. Baxter LT, Jain RK. 1989. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res 37(1):77-104.
9. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. 2007. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449(7162):557-U554.
10. Jain RK,Ward-Hartley K. 1984. Tumor blood flow-characterization, modifications, and role in hyperthermia. IEEE Trans Sonics Ultrasonics 31(5):504-525.
11. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. 2006. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 98(5):335-344.
12. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Bl ättlerWA, Goldmacher VS. 2006. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66(6):3214-3221.
13. Rosania GR, Lee JW, Ding L, Yoon HS, Chang YT. 2003. Combinatorial approach to organelle-targeted fluorescent library based on the styryl scaffold. J Am Chem Soc 125(5):1130-1131.
14. Dreher MR, Liu WG, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. 2006. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 98(5):335-344.
15. Gerlowski L, Jain RK. 1986. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 31:288-305.
16. Champion JA, Mitragotri S. 2006. Role of target geometry in phagocytosis. Proc Natl Acad Sci USA 103(13):4930-4934.
17. Harris TJ, Green JJ, Fung PW, Langer R, Anderson DG, Bhatia SN. 2010. Tissue-specific gene delivery via nanoparticle coating. Biomaterials 31(5):998-1006.
18. Choi HS, Liu W, Liu F, Nasr K, Misra P, Bawendi MG, Frangioni JV. 2010. Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol 5(1):42-47.
19. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA. 2004. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10(20):7063-7070.
20. Zhang X, Shedden K, Rosania GR. 2006. A cell-based molecular transport simulator for pharmacokinetic prediction and cheminformatic exploration. Mol Pharm 3(6):704-716.
21. Rhoden JJ, Wittrup KD. 2012. Dose dependence of intratumoral perivascular distribution of monoclonal antibodies. J Pharm Sci 101(2):860-867.
22. Weissleder R, Tung CH, Mahmood U, Bogdanov A. 1999. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 17(4):375-378.
23. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, Hsu YT, Dubinett SM, Phelps ME, Czernin J, Weber WA. 2008. Evaluation of [F-18]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 35(6):1089-1099.
24. Thurber GM, Weissleder R. 2011. Quantitating antibody uptake in vivo: Conditional dependence on antigen expression levels. Mol Imaging Biol 13(4):623-632.
25. Cai WB, Chen K, He LN, Cao QH, Koong A, Chen XY. 2007. Quantitative PET of EGFR expression in xenograft-bearing mice using Cu-64-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 34(6):850-858.
26. McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM. 2009. Associations between the uptake of In-111-DTPAtrastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging 36(1):81-93.
27. Aerts H, Dubois L, Perk L, Vermaelen P, van Dongen G, Wouters BG, Lambin P. 2009. Disparity between in vivo EGFR expression and Zr-89-labeled cetuximab uptake assessed with PET. J Nucl Med 50(1):123-131.
28. Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, Brechbiel MW. 2008. Cetuximab: Preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 23(5):619-631.
29. Mullani NA, Herbst RS, O'Neil RG, Gould KL, Barron BJ, Abbruzzese JL. 2008. Tumor blood flow measured by PET dynamic imaging of first-pass F-18-FDG uptake: A comparison with O-15-labeled water-measured blood flow. J Nucl Med 49(4):517-523.
30. Patlak CS, Blasberg RG, Fenstermacher JD. 1983. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3(1):1-7.
31. Thurber GM, Yang KS, Reiner T, Kohler RH, Sorger P, Mitchison T,Weissleder R. 2013. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat Commun 4:1504.
32. Venkatasubramanian R, Arenas RB, Henson MA, Forbes NS. 2010. Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response. Br J Cancer 103(4):486-497.
33. Hauert S, Berman S, Nagpal R, Bhatia SN. 2013. A computational framework for identifying design guidelines to increase the penetration of targeted nanoparticles into tumors. Nano Today 8(6):566-576.
34. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. 2012. Practical theoretic guidance for the design of tumor-targeting agents. In: Methods in enzymology: Protein engineering for therapeutics; Wittrup KD, Verdine GL, Eds. Vol. 503. pp 255-268. Elsevier, Waltham, MA
35. Poulin P, Theil FP. 2002. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91(5):1358-1370.
36. Peters SA. 2008. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet 47(4):261-275.
37. Rowland M, Peck C, Tucker G. 2011. Physiologically-based pharmacokinetics in drug development and regulatory science. In: Annual review of pharmacology and toxicology; Cho AK, Ed. Vol. 51. Palo Alto: Annual Reviews, pp 45-73.
38. Rodgers T, Rowland M. 2007. Mechanistic approaches to volume of distribution predictions: Understanding the processes. Pharm Res 24(5):918-933.
39. Ferl GZ, Wu AM, DiStefano JJ. 2005. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal fc receptor (FcRn). Ann Biomed Eng 33(11):1640-1652.
40. Garg A, Balthasar JP. 2007. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRnknockout mice. J Pharmacokinet Pharmacodyn 34(5):687-709.
41. Mager DE. 2006. Quantitative structure-pharmacokinetic/ pharmacodynamic relationships. Adv Drug Deliv Rev 58(12-13):1326-1356.
42. Thurber GM, Weissleder R. 2011. A systems approach for tumor pharmacokinetics. PLoS One 6(9).
43. Graham J, Muhsin M, Kirkpatrick P. 2004. Cetuximab. Nat Rev Drug Discov 3(7):549-550.
44. Astsaturov I, Cohen RB, Harari PM. 2006. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 6(8):691-710.
45. Thurber GM, Schmidt MM,Wittrup KD. 2008. Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60(12):1421-1434.
46. Lammler G, Herzog H, Saupe E, Schutze HR. 1971. Chemotherapeutic studies on Litomosoides carinii infection of Mastomys natalensis.1. The filaricidal action of 2,6-bis-benzimidazoles. Bull World Health Organ 44(6):751-756.
47. Chaplin DJ, Olive PL, Durand RE. 1987. Intermittent blood-flow in a murine tumor-Radiobiological effects. Cancer Res 47(2):597-601.
48. Trotter MJ, Chaplin DJ, Olive PL. 1989. Use of a carbocyanine dye as a marker of functional vasculature in murine tumors. Br J Cancer 59(5):706-709.
49. Coleman PJ, Brashear KM, Askew BC, Hutchinson JH, McVean CA, Duong LT, Feuston BP, Fernandez-Metzler C, Gentile MA, Hartman GD, Kimmel DB, Leu CT, Lipfert L, Merkle K, Pennypacker B, Prueksaritanont T, Rodan GA, Wesolowski GA, Rodan SB, Duggan ME. 2004. Nonpeptide alpha(v)beta(3) antagonists. Part 11: Discovery and preclinical evaluation of potent alpha v beta(3) antagonists for the prevention and treatment of osteoporosis. J Med Chem 47(20):4829-4837.
50. Kossodo S, PickarskiM, Lin S-A, Gleason A, Gaspar R, Buono C,Ho G, Blusztajn A, Cuneo G, Zhang J, Jensen J, Hargreaves R, Coleman P, Hartman G, Rajopadhye M, Duong LT, Sur C, Yared W, Peterson J, Bednar B. 2009. Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). Mol Imaging Biol 12(5):488-499.
51. Ferl GZ, Dumont RA, Hildebrandt IJ, Armijo A, Haubner R, Reischl G, Su H, Weber WA, Huang SC. 2009. Derivation of a compartmental model for quantifying Cu-64-DOTA-RGD kinetics in tumor-bearing mice. J Nucl Med 50(2):250-258.
52. LalandeME, Ling V, Miller RG. 1981. Hoechst 33342 dye uptake as a probe of membrane permeability changes in mammalian cells. Proc Natl Acad Sci USA 78(1):363-367.
53. Grandjean TR, Chappell MJ, Yates JT, Jones K, Wood G, Coleman T. 2011. Compartmental modelling of the pharmacokinetics of a breast cancer resistance protein. Comput Methods Programs Biomed 104(2):81-92.
54. Bolte S, Cordelieres FP. 2006. A guided tour into subcellular colocalization analysis in light microscopy. J Micrsocopy 224:213-232.
55. Smith KA, Hill SA, Begg AC, Denekamp J. 1988. Validation of the Fluorescent Dye Hoechst 33342 as a vascular space marker in tumors. Br J Cancer 57(3):247-253.
56. Thurber GM, Zajic SC, Wittrup KD. 2007. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 48(6):995-999.
57. Oliveira S, Cohen R, Walsum MS, van Dongen GA, Elias SG, van Diest PJ, Mali W, van Bergen En, Henegouwen PM. 2012. A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies. EJNMMI Res 2(1):50.
58. Balaz S. 2009. Modeling kinetics of subcellular disposition of chemicals. Chem Rev 109:1793-1899.
59. Arndt-Jovin DJ, Jovin TM. 1977. Analysis and sorting of living cells according to deoxyribonucleic acid content. J Histochem Cytochem 25(7):585-589.
60. Thurber GM, Figueiredo JL, Weissleder R. 2009. Multicolor fluorescent intravital live microscopy (FILM) for surgical tumor resection in a mouse xenograft model. PLoS ONE 4(11):e8053.
61. Poulin P, Theil FP. 2000. A Priori prediction of tissue: Plasma partition coefficients of drugs to facilitate the use of physiologicallybased pharmacokineticmodels in drug discovery. J Pharm Sci 89(1):16-35.
62. Boucher Y, Baxter LT, Jain RK. 1990. Interstitial pressuregradients in tissue-isolated and subcutaneous tumors-Implications for therapy. Cancer Res 50(15):4478-4484.
63. Jain RK, Baxter L. 1988. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 48:7022-7032.
64. Swartz MA. 2001. The physiology of the lymphatic system. Adv Drug Deliv Rev 50(1-2):3-20.
65. Thurber GM,Wittrup KD. 2008. Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res 68:3334-3341.
66. Adams G, Schier R, McCall A, Simmons H, Horak E, Alpaugh K, Marks J, Weiner L. 2001. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res 61:4750-4755.
67. Rudnick SI, Lou JL, Shaller CC, Tang Y, Klein-Szanto AJP,Weiner LM, Marks JD, Adams GP. 2011. Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors. Cancer Res 71(6):2250-2259.
68. Heijn M, Roberge S, Jain RK. 1999. Cellular membrane permeability of anthracyclines does not correlate with their delivery in a tissue-isolated tumor. Cancer Res 59(17):4458-4463.
69. Vaupel P, Kallinowski F, Okunieff P. 1989. Blood-flow, oxygen and nutrient supply, andmetabolic microenvironment of human-tumors-A review. Cancer Res 49(23):6449-6465.
70. Baxter L, Zhu H, Mackensen D, Jain RK. 1994. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54:1517-1528.
71. Solomon B, Binns D, Roselt P,Weibe LI, McArthur GA, Cullinane C, Hicks RJ. 2005. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol Cancer Ther 4(9):1417-1422.
72. Mü ller M, Keimling R, Lang S, Pauli J, Dahmen U, Dirsch O. 2009. Estimating blood flow velocity in liver vessels. In: Bildverarbeitung f ür die Medizin 2009; Meinzer H-P, Deserno T, Handels H, Tolxdorff T, Eds. Berlin Heidelberg: Springer, pp 36-40.
73. Sturesson C, Milstein DMJ, Post I, Maas AM, van Gulik TM. 2013. Laser speckle contrast imaging for assessment of liver microcirculation. Microvasc Res 87:34-40.
74. Jain RK. 1999. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 01:241-263.
75. Baker J, Lindquist K, Huxham L, Kyle A, Sy J, Minchinton A. 2008. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 14(7):2171-2179.
76. Steffen AC, Orlova A, Wikman M, Nilsson FY, Stahl S, Adams GP, Tolmachev V, Carlsson J. 2006. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 33(6):631-638.
77. Devaraj NK, Thurber GM, Keliher EJ, Marinelli B, Weissleder R. 2012. Reactive polymer enables efficient in vivo bioorthogonal chemistry. Proc Natl Acad Sci USA 109(13):4762-4767.
78. Keliher EJ, Reiner T, Thurber GM, Upadhyay R, Weissleder R.2012. Efficient 18F-labeling of synthetic exendin-4 analogues for imaging beta cells. Chem Open1 (4): 177-183.
79. Baish JW, Netti PA, Jain RK. 1997. Transmural coupling of fluid flow inmicrocirculatory network and interstitium in tumors. Microvasc Res 53(2):128-141.
80. Trotter MJ, Olive PL, Chaplin DJ. 1990. Effect of vascular marker Hoechst-33342 on tumor perfusion and cardiovascular function in the mouse. 62(6):903-908.
81. Thurber G. 2011. Kinetics of antibody penetration into tumors. In: Targeted radionuclide therapy; Speer TW, Ed. Philadelphia: Lippincott Williams and Wilkins, pp 168-181.
82. van Osdol W, Fujimori K, Weinstein J. 1991. An analysis of monoclonal antibody distribution in microscopic tumor nodules: Consequences of a "Binding Site Barrier". Cancer Res 51:4776-4784.
83. Thurber G, Schmidt M, Wittrup KD. 2008. Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29(2):57-61.
84. Huang S, Endo RI, Nemerow GR. 1995. Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol 69(4):2257-2263.
85. Perrault SD,Walkey C, Jennings T, Fischer HC, ChanWCW. 2009. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 9(5):1909-1915.
86. Yang Z, Leon J, Martin M, Harder JW, Zhang R, Liang D, Lu W, Tian M, Gelovani JG, Qiao A, Li C. 2009. Pharmacokinetics and biodistribution of near-infrared fluorescence polymeric nanoparticles. Nanotechnology 20(16):11.
87. Choi HS, Ipe BI, Misra P, Lee JH, Bawendi MG, Frangioni JV. 2009.Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett 9(6):2354-2359.
88. Nahrendorf M, Waterman P, Thurber G, Groves K, Rajopadhye M, Panizzi P, Marinelli B, Aikawa E, PittetMJ, Swirski FK,Weissleder R. 2009.Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol 29(10):1444-U1489.
89. Blumenthal RD, Fand I, Sharkey RM, Boerman OC, Kashi R, Goldenberg DM. 1991. The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies-An autoradiographic study. Cancer Immunol Immunother 33(6):351-358.
90. Thurber GM, Wittrup KD. 2012. A mechanistic compartmental model for total antibody uptake in tumors. J Theor Biol 314:57-68.
91. Jain RK. 2005. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307(5706):58-62.